Antisense Therapeutics logo

ANP - Antisense Therapeutics Share Price

A$0.21 -0.0  -8.7%

Last Trade - 22/01/21

Sector
Healthcare
Size
Small Cap
Market Cap £58.0m
Enterprise Value £55.8m
Revenue £17.3k
Position in Universe 812th / 1840
Bullish
Bearish
Unlock ANP Revenue
Momentum
Relative Strength (%)
1m +57.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3.92 1.13 0.14 0.026 0.066 0.031 4.05 3.20 -62.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, AntisenseTherapeutics Limited revenues decreased 54% to A$31K. Netloss increased from A$2.9M to A$5.9M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Administrative expenses increase of 25% to A$2M(expense), Research and development expenses increase of 8%to A$1.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ANP Revenue Unlock ANP Revenue

Net Income

ANP Net Income Unlock ANP Revenue

Normalised EPS

ANP Normalised EPS Unlock ANP Revenue

PE Ratio Range

ANP PE Ratio Range Unlock ANP Revenue

Dividend Yield Range

ANP Dividend Yield Range Unlock ANP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ANP EPS Forecasts Unlock ANP Revenue
Profile Summary

Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.

Directors
Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated November 13, 2000
Public Since December 20, 2001
No. of Shareholders: n/a
No. of Employees: 8
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 488,785,281
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ANP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ANP
Upcoming Events for ANP
Frequently Asked Questions for Antisense Therapeutics
What is the Antisense Therapeutics share price?

As of 22/01/21, shares in Antisense Therapeutics are trading at A$0.21, giving the company a market capitalisation of £58.0m. This share price information is delayed by 15 minutes.

How has the Antisense Therapeutics share price performed this year?

Shares in Antisense Therapeutics are currently trading at A$0.21 and the price has moved by 0.176k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Antisense Therapeutics price has moved by 0.181k% over the past year.

What are the analyst and broker recommendations for Antisense Therapeutics?

There are no analysts currently covering Antisense Therapeutics.

When will Antisense Therapeutics next release its financial results?

Antisense Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Antisense Therapeutics dividend yield?

Antisense Therapeutics does not currently pay a dividend.

Does Antisense Therapeutics pay a dividend?

Antisense Therapeutics does not currently pay a dividend.

When does Antisense Therapeutics next pay dividends?

Antisense Therapeutics does not currently pay a dividend.

How do I buy Antisense Therapeutics shares?

To buy shares in Antisense Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Antisense Therapeutics?

Shares in Antisense Therapeutics are currently trading at A$0.21, giving the company a market capitalisation of £58.0m.

Where are Antisense Therapeutics shares listed? Where are Antisense Therapeutics shares listed?

Here are the trading details for Antisense Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ANP
What kind of share is Antisense Therapeutics?

Based on an overall assessment of its quality, value and momentum, Antisense Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Antisense Therapeutics share price forecast 2021?

Shares in Antisense Therapeutics are currently priced at A$0.21. At that level they are trading at 80.95% discount to the analyst consensus target price of 0.00.

Analysts covering Antisense Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.408 for the next financial year.

How can I tell whether the Antisense Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Antisense Therapeutics. Over the past six months, the relative strength of its shares against the market has been 83.03%. At the current price of A$0.21, shares in Antisense Therapeutics are trading at 0.120k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Antisense Therapeutics PE Ratio?

We were not able to find PE ratio data for Antisense Therapeutics.

Who are the key directors of Antisense Therapeutics?

Antisense Therapeutics's management team is headed by:

Robert Moses - NEC
Mark Diamond - MDR
Graham Mitchell - NID
George Tachas - OTH
Phillip Hains - CFO
Nuket Desem - OTH
William Goolsbee - NED
Gary Pace - NED
Gil Price - OTH
Who are the major shareholders of Antisense Therapeutics?

Here are the top five shareholders of Antisense Therapeutics based on the size of their shareholding:

Platinum Investment Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 4.76% (27.3m shares)
Australian Ethical Investment Ltd. Investment Advisor
Percentage owned: 4.13% (23.7m shares)
CityCastle Pty. Ltd. Corporation
Percentage owned: 3.27% (18.8m shares)
Mutual Investments Pty Ltd Corporation
Percentage owned: 1.74% (10.00m shares)
Esarad Holdings Pty. Ltd. Corporation
Percentage owned: 1.65% (9.50m shares)
Similar to ANP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.